Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL
February 29th 2024In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.
Read More
Access to Cancer Care Alleviates Racial Disparities in CLL/SLL
February 19th 2024No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.
Read More
Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL
February 6th 2024Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.
Read More
ASH Abstracts Showcase Effective Treatments for MM, CLL, FL
January 20th 2024Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).
Read More
Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL
January 12th 2024A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Read More
Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups
January 10th 2024Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
Read More
Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era
January 5th 2024An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
Read More